Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5775595 | 0.81 | SIGMAR1 (0.50) | SIGMAR1MC4RCOMTLMNAALDH1A1 | |
| SCHEMBL5773487 | 0.77 | SIGMAR1 (0.46) | SIGMAR1MC4RCOMTLMNAALDH1A1 | |
| SCHEMBL5778759 | 0.77 | SIGMAR1 (0.46) | SIGMAR1MC4RCOMTLMNAALDH1A1 | |
| SCHEMBL1994688 | 0.77 | SIGMAR1 (0.42) | SIGMAR1MC4RCOMTLMNAALDH1A1 | |
| SCHEMBL5776436 | 0.77 | SIGMAR1 (0.42) | SIGMAR1MC4RCOMTLMNAALDH1A1 | |
| SCHEMBL23268618 | 0.77 | SIGMAR1 (0.49) | SIGMAR1MC4RCOMTLMNAALDH1A1 | |
| SCHEMBL5776762 | 0.77 | SIGMAR1 (0.49) | SIGMAR1MC4RCOMTLMNAALDH1A1 | |
| SCHEMBL10095281 | 0.77 | SIGMAR1 (0.49) | SIGMAR1MC4RCOMTLMNAALDH1A1 | |
| SCHEMBL1999832 | 0.74 | SIGMAR1 (0.42) | SIGMAR1MC4RCOMTLMNAALDH1A1 | |
| SCHEMBL1290487 | 0.74 | COMT (0.41) | SIGMAR1COMTALDH1A1ACHEADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | SIGMAR1 795/4885MC4R 1064/4885COMT 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.